Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

NNC0165-1875

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Novo Nordisk · Phase 2 · Completed · Enrollment 120

NCT04969939

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 2.4 mg and NNC0165-1875 2.0 mgn/rn/rn/rn/r
Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)n/rn/rn/rn/r
Semaglutide 2.4 mg and NNC0165-1875 1.0 mgn/rn/rn/rn/r
Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)n/rn/rn/rn/r

Not shown

  • Semaglutide 2.4 mg and NNC0165-1875 2.0 mg: endpoint not reported
  • Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg): endpoint not reported
  • Semaglutide 2.4 mg and NNC0165-1875 1.0 mg: endpoint not reported
  • Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg): endpoint not reported